Pfizer Reinforces its Pain Relief Franchise with Deal to Buy Development Partner Icagen
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 8 (Table of Contents)
Published: 2 Aug-2011
DOI: 10.3833/pdr.v2011.i8.1515 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Pfizer has agreed to buy the 89% of its long-time development partner Icagen that it does not already own for US$6 per share in order to expand its capabilities in the pain relief therapy area...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS